Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of molnupiravir powder in China. Welcome to wholesale bulk high quality molnupiravir powder for sale here from our factory. Good service and reasonable price are available.
Molnupiravir Powder is a precursor form of oral antiviral medication, with its active ingredient being Molnupiravir, primarily used for the treatment of specific viral infections. The appearance is usually white to off white crystalline powder, with a fine and uniform texture, no visible particles or clumps, good flowability, easy to package and prepare solutions, and soluble in water.
It is a nucleoside analogue with a structure similar to the nucleotides required for viral RNA replication, such as cytidine. After entering the host cell, the drug is recognized by the viral RNA polymerase and integrated into the newly synthesized viral RNA strand, resulting in a large number of erroneous mutations (such as base substitutions, insertions, or deletions) in the viral genome. The high mutation rate prevents the virus from synthesizing fully functional proteins, ultimately preventing it from completing the replication cycle and being cleared by the host immune system. It is used to treat adult patients with mild to moderate COVID-19 infection, and there are high risk factors for progression to severe disease (such as age ≥ 60 years, obesity, diabetes, chronic heart and lung diseases, etc.). Medication should be started within 5 days after the onset of symptoms to maximize efficacy.
At the same time, our company not only provides pure powders, but also tablets and injections. If needed, please feel free to contact us at any time.
Our products
 |
 |
| Product Name | Molnupiravir Powder | Molnupiravir Tablet | Molnupiravir Capsules | Molnupiravir Injection |
| Product Type | Powder | Tablet | Capsules | liquid |
| Product Purity | ≥99% | ≥99% | ≥99% | ≥99% |
| Product Specifications | 100g/1kg/etc. | 200mg/400mg/800mg | 200mg/400mg/800mg | 200mg |
| Product Form | Organic synthesis | Take Orally | Take Orally | Organic synthesis |
 |
 |
Molnupiravir COA
 |
||
| Certificate of Analysis | ||
| Compound name | Molnupiravir | |
| Grade | Pharmaceutical grade | |
| CAS No. | 2349386-89-4 | |
| Quantity | Customized | |
| Packaging standard | Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090035 | |
| MFG | Jan 9th 2025 | |
| EXP | Jan 8th 2028 | |
| Structure |  |
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.37% |
| Loss on drying | ≤1.0% | 0.28% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.80% |
| Single impurity | <0.8% | 0.44% |
| Total microbial count | ≤750cfu/g | 80 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
|
|
||
Molnupiravir Powder is an important breakthrough in the field of antiviral drug research and development in recent years. As one of the first approved oral anti COVID-19 drugs in the world, its unique mechanism of action and convenient administration mode provide new tools for the prevention and control of COVID-19.
Mechanism of action of Molnupiravir: a 'lethal mutagen' targeting viral RNA
Design Logic of Nucleoside Analogues
Molnupiravir belongs to nucleoside analogue, and its chemical structure is highly similar to the natural nucleosides required for viral RNA replication, such as cytidine triphosphate (CTP). This similarity allows it to be "mistaken" as a normal substrate by viral RNA dependent RNA polymerase (RdRp) and integrated into newly synthesized viral RNA strands.
The mechanism of inducing catastrophic mutations in the viral genome
The active form of Molnupiravir (β - D-N4-hydroxycytidine triphosphate, NHC-TP), when substituted for CTP in viral RNA strands, triggers mutations through two pathways:
Direct mutagenesis: NHC-TP can form unstable base pairs with adenosine (A) or guanosine (G), leading to the insertion of incorrect bases in the next round of replication (such as A → G or G → A substitutions).
Indirect mutagenesis: NHC-TP integration may alter the local conformation of RNA strands, inducing RdRp "slippage" and resulting in base insertions or deletions (indels).
Mutation accumulation effect: single integration may only cause individual mutations, but viral RNA replication is extremely fast (COVID-19 can produce about 10 ¹² viral particles every day), resulting in exponential accumulation of mutations in the virus population. When the mutation rate exceeds the virus tolerance threshold (usually requiring a mutation frequency of>1%), the viral genome will lose functional integrity, unable to synthesize effective proteins or complete assembly, and ultimately be cleared by the host immune system.
Molecular basis of broad-spectrum antiviral potential
The target of Molnupiravir (RdRp) is highly conserved in RNA viruses, and its mutagenic mechanism does not depend on virus specific protein structure. Therefore, it has potential activity against various RNA viruses, including:
Coronavirus family: SARS-CoV-2 (original strain and Alpha, Beta, Delta, Omicron and other variants) SARS-CoV,MERS-CoV.
Orthomyxoviridae: influenza A virus (IAV), influenza B virus (IBV).
Paramyxoviridae: respiratory syncytial virus (RSV), measles virus.
Small RNA virus family: Norovirus, poliovirus.
Molnupiravir's core indication: early treatment of COVID-19 infection
Strict definition of indications
According to the approval opinions of the World Health Organization (WHO) and national drug regulatory agencies (such as FDA, EMA), the indications for Molnupiravir are:
Population: adult patients with mild to moderate COVID-19 infection (≥ 18 years old).
Risk stratification: There must be high-risk factors for progression to severe illness, including:
Age ≥ 60 years old;
Not vaccinated with COVID-19 vaccine or the immune response is insufficient;
Basic diseases (such as obesity, diabetes, chronic heart and lung disease, chronic kidney disease, immunosuppression);
Late pregnancy (weighing the pros and cons, usually contraindicated).
Time window: Start treatment within 5 days after symptoms appear to maximize the window period for inhibiting virus replication.
Quantitative evidence of clinical efficacy
Key trial (MOVe OUT): 1433 unvaccinated high-risk non hospitalized patients were randomly assigned to either the Molnupiravir group (800 mg, twice daily, 5 days) or the placebo group.
Primary endpoint (hospitalization or death within 28 days) incidence: Molnupiravir group: 7.3% (28/385); Placebo group: 10.1% (37/365); Relative Risk Reduction (RRR): 28% (95% CI: 2% -48%).
Secondary endpoint: Rate of viral load decline: On day 5, the viral load in the Molnupiravir Powder group decreased by approximately 0.3 log ₁₀ copy/mL compared to baseline (p=0.02); Symptom relief time: median shortened by 1 day (10 days vs 11 days, p=0.07).
Comparison of therapeutic effects with similar drugs
| Drug | Medication method | For the crowd | Reduced risk of hospitalization/death | Shortened symptom relief time | Special advantages |
| Molnupiravir | Take Orally | High risk mild to moderate patients (symptoms ≤ 5 days) | 28%-30% | 1 day | Widely effective against mutant strains without dose adjustment |
| Paxlovid | Take Orally | High risk mild to moderate patients (symptoms ≤ 5 days) | 88%-89% | 4 day | Stronger therapeutic effect, but attention should be paid to drug interactions |
| Remdesivir | Vein | Inpatient (aerobic therapy) | 5% | No significant difference | The only approved intravenous antiviral drug |
| Neutralizing antibody | Injection | Mild to moderate patients (symptoms ≤ 10 days) | 70%-85% | 2-3 days | Effective for immunocompromised patients |
Clinical application scenario of Molnupiravir: full process management from outpatient to community
Early Outpatient Treatment: A Key Step in Blocking Disease Progression
Target population
High-risk COVID-19 patients in the community, especially those who are unable to vaccinate or have insufficient immune response after vaccination (such as the elderly, organ transplant recipients).
Medication timing
Start as soon as possible after diagnosis (preferably within 48 hours of symptom onset) to reduce peak viral load and transmission risk.
Treatment advantages
Oral administration without the need for intravenous injection or hospitalization observation, reducing the occupation of medical resources; 5-day short course of treatment, high patient compliance;
Maintain therapeutic efficacy against Delta, Omicron and other variants, reducing treatment failures caused by viral mutations.
Priority selection for areas with limited resources
Accessibility advantage
Powder formulations are easy to transport and store (stored at room temperature), suitable for areas lacking cold chain facilities;
Merck has signed a voluntary licensing agreement with generic drug companies to reduce procurement costs in low - and middle-income countries.
Public Health Value
Early treatment can reduce community transmission and lower the risk of epidemic outbreaks;
Reduce the burden on hospitals and avoid a run on the healthcare system.
Flexible Application in Special Situations
Post exposure prophylaxis (PEP)
Animal experiments have shown that Molnupiravir can reduce the risk of infection in close contacts, but human research data is limited and it is currently not recommended as a routine preventive medication.
Immunodeficiency patients
Molnupiravir can be used as an alternative to neutralizing antibody or Paxlovid for patients with B cell or T cell dysfunction (such as patients with AIDS and after chemotherapy of blood tumors), but it is necessary to monitor the rebound of viral load.
Medication during pregnancy
Animal experiments have shown that high doses may cause fetal bone deformities, therefore they are contraindicated during pregnancy; Breastfeeding women should pause breastfeeding for 5 days after the end of treatment.
Potential of combination therapy: breaking through the efficacy bottleneck of single drug therapy
Paxlovid blocks viral polyprotein cleavage by inhibiting 3CL protease, complementing the mutagenic mechanism of Molnupiravir Powder; Animal experiments have shown that the combination of the two can further reduce viral load (1-2 log ₁₀ copy/mL lower than monotherapy). Ritonavir in Paxlovid is a strong inhibitor of CYP3A4, which may affect Molnupiravir metabolism (although the latter is mainly excreted by the kidneys, adverse reactions need to be monitored for superposition);
Exploration of Combined Use with Immune Modulators
Molnupiravir rapidly reduces viral load, buying time for the immune system; Immune modulators such as baritinib and tocilizumab can inhibit excessive inflammatory responses and reduce the risk of severe illness.
The RECORDY trial in the UK showed that the combination of baritinib and Molnupiravir did not significantly reduce mortality, but may shorten hospitalization time (median shortened by 1 day)
Frequently Asked Questions
How rich are its crystal forms?
+
-
Up to now, at least 7 crystal forms have been identified, among which two anhydrous substances (Type I and Type II) coexist during large-scale production, posing a serious challenge to the formulation process. The early discovery of two anhydrous polymorphs has raised questions about stability, solubility, and bioavailability. Subsequent studies have shown that crystal form VII can also be obtained through specific crystallization conditions, such as using isobutanol. The study published in Crystal Growth&Design in 2024 further systematically analyzed the polymorphic forms and solvates of Monoravir, revealing its complex solid-state transformation relationships.
Under whose 'attack' is it most vulnerable? --Alkali solution is its' natural enemy '
+
-
Monoravir is extremely sensitive to alkaline hydrolysis, and its degradation rate under alkaline conditions far exceeds other stress conditions such as acid, oxidation, light, and heat. Research has found that although it exhibits stability under oxidative, neutral, and solar induced conditions, it is highly susceptible to degradation under alkaline hydrolysis conditions. Its alkaline degradation follows a quasi first order kinetic model.
Who is the term 'NHC' often mentioned in literature? --Both metabolites and major degradation products
+
-
N4 hydroxycytidine is not only the active metabolite of Monoravir in vivo (in the form of antiviral activity), but also its main degradation product. This dual identity of being both a metabolite and a degradation product makes simultaneous detection of MLN and NHC crucial for quality control in formulation stability monitoring and in vivo pharmacokinetic analysis.
How long can it "live" in light avoiding oral liquid? --Only 14 days under refrigeration conditions
+
-
When formulated into syrup from capsules (such as using Ora Sweet SF as a mixed solvent), the shelf life when stored in a refrigerator (2-8 ° C) is only 14 days. Research has shown that a suspension containing 800 mg of Monoravir per 10 mL has a shelf life (BUD) of 14 days. This is a safety window set considering its stability in aqueous solutions, and exceeding this period may affect drug efficacy or increase impurities due to degradation.
How to distinguish "twin" crystal types in industrial production? --Using synchrotron radiation and crystal structure prediction
+
-
Due to the extreme similarity between crystal forms I and II under conventional detection methods, Merck scientists had to use high-resolution powder diffraction combined with crystal structure prediction technology to accurately confirm. In order to ensure the quality of drugs during the urgent epidemic period, the R&D team used single crystal X-ray diffraction to determine the structure of crystal form I, and utilized Rietveld refinement of synchrotron radiation powder diffraction data to determine the structure of crystal form II, supplemented by crystal structure prediction to verify the reliability of the results.
Hot Tags: molnupiravir powder, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Oxytocin powder, Amitriptyline Hydrochloride Powder CAS 549 18 8, Promethazine Hydrochloride Powder CAS 58 33 3, Articaine Hcl powder, Cyclosporin A, ciprofloxacin powder